AR071684A1 - Compuestos para el tratamiento de la hepatitis c - Google Patents

Compuestos para el tratamiento de la hepatitis c

Info

Publication number
AR071684A1
AR071684A1 ARP090101641A ARP090101641A AR071684A1 AR 071684 A1 AR071684 A1 AR 071684A1 AR P090101641 A ARP090101641 A AR P090101641A AR P090101641 A ARP090101641 A AR P090101641A AR 071684 A1 AR071684 A1 AR 071684A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
hydrogen
dialkylamino
substituted
Prior art date
Application number
ARP090101641A
Other languages
English (en)
Spanish (es)
Inventor
Xiaofan Zheng
Carl P Bergstrom
Min Ding
Robert G Gentles
Scott W Martin
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40786514&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR071684(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR071684A1 publication Critical patent/AR071684A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ARP090101641A 2008-05-06 2009-05-06 Compuestos para el tratamiento de la hepatitis c AR071684A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5074308P 2008-05-06 2008-05-06

Publications (1)

Publication Number Publication Date
AR071684A1 true AR071684A1 (es) 2010-07-07

Family

ID=40786514

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090101641A AR071684A1 (es) 2008-05-06 2009-05-06 Compuestos para el tratamiento de la hepatitis c

Country Status (19)

Country Link
US (1) US8133884B2 (cg-RX-API-DMAC7.html)
EP (1) EP2280975B1 (cg-RX-API-DMAC7.html)
JP (1) JP2011520810A (cg-RX-API-DMAC7.html)
KR (1) KR20110015588A (cg-RX-API-DMAC7.html)
CN (1) CN102083834A (cg-RX-API-DMAC7.html)
AR (1) AR071684A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009244409A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0915130A2 (cg-RX-API-DMAC7.html)
CA (1) CA2723683A1 (cg-RX-API-DMAC7.html)
CL (1) CL2009001089A1 (cg-RX-API-DMAC7.html)
CO (1) CO6290645A2 (cg-RX-API-DMAC7.html)
EA (1) EA201001748A1 (cg-RX-API-DMAC7.html)
IL (1) IL208753A0 (cg-RX-API-DMAC7.html)
MX (1) MX2010011921A (cg-RX-API-DMAC7.html)
NZ (1) NZ588556A (cg-RX-API-DMAC7.html)
PE (1) PE20091879A1 (cg-RX-API-DMAC7.html)
TW (1) TW200951135A (cg-RX-API-DMAC7.html)
WO (1) WO2009137454A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201007649B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
ATE531373T1 (de) 2008-03-27 2011-11-15 Bristol Myers Squibb Co Aromatische heterocyclische kondensierte indolobenzadiazepin-hcv-ns5b-inhibitoren
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
WO2012087833A1 (en) 2010-12-22 2012-06-28 Abbott Laboratories Hepatitis c inhibitors and uses thereof
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
US9073943B2 (en) 2012-02-10 2015-07-07 Lupin Limited Antiviral compounds with a dibenzooxaheterocycle moiety
EP3091022A3 (en) * 2012-07-18 2016-12-14 Bristol-Myers Squibb Holdings Ireland Methods and intermediates for the preparation of (4bs,5ar)-12-cyclohexyl-n-(n,n-dimethylsulfamoyl)-3- methoxy-5a-((1r,5s)-3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-a]indole-9-carboxamide

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005080399A1 (ja) 2004-02-24 2005-09-01 Japan Tobacco Inc. 4環縮合複素環化合物及びそのhcvポリメラーゼ阻害剤としての利用
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
RU2007119562A (ru) 2004-10-26 2008-12-10 Институто Ди Ричерке Ди Биолоджиа Молеколаре П Анджелетти Спа (It) Тетрациклические производные индолов в качестве противовирусных агентов
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
US7456166B2 (en) 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
DE602007006796D1 (de) 2006-05-25 2010-07-08 Bristol Myers Squibb Co Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b-hemmer
WO2007140200A2 (en) 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
US7452876B2 (en) 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7541351B2 (en) 2007-01-11 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7517872B2 (en) 2007-02-22 2009-04-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538102B2 (en) 2007-03-14 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7521444B2 (en) 2007-03-14 2009-04-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7547690B2 (en) 2007-03-14 2009-06-16 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7541353B2 (en) 2007-03-14 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538103B2 (en) 2007-03-15 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US20090018163A1 (en) 2007-07-11 2009-01-15 Bristol-Myers Squibb Company Substituted Heterocyclic Ethers and Their Use in CNS Disorders
US7652004B2 (en) 2007-08-09 2010-01-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7642251B2 (en) 2007-08-09 2010-01-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8129367B2 (en) 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US8124601B2 (en) 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C

Also Published As

Publication number Publication date
CO6290645A2 (es) 2011-06-20
CA2723683A1 (en) 2009-11-12
WO2009137454A1 (en) 2009-11-12
MX2010011921A (es) 2010-11-30
EP2280975B1 (en) 2014-01-01
US20090280083A1 (en) 2009-11-12
EA201001748A1 (ru) 2011-06-30
CL2009001089A1 (es) 2011-04-29
EP2280975A1 (en) 2011-02-09
NZ588556A (en) 2012-06-29
AU2009244409A1 (en) 2009-11-12
TW200951135A (en) 2009-12-16
IL208753A0 (en) 2010-12-30
KR20110015588A (ko) 2011-02-16
US8133884B2 (en) 2012-03-13
BRPI0915130A2 (pt) 2019-09-24
PE20091879A1 (es) 2009-12-19
ZA201007649B (en) 2012-04-25
JP2011520810A (ja) 2011-07-21
CN102083834A (zh) 2011-06-01

Similar Documents

Publication Publication Date Title
CO6251359A2 (es) Compuestos de indolobenzazepina sustituida por heteroarilo
AR065772A1 (es) Compuestos de indolobenzazepina para el tratamiento de la hepatitis c. composiciones farmaceuticas.
AR055165A1 (es) Inhibidores ns5b de vhc de indolobenzacepina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de la hepatitis c.
AR061008A1 (es) Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo
AR061053A1 (es) Inhibidores ns5b del virus de hepatitis c de indolobenzazepina fusionados a ciclopropilo
AR035991A1 (es) Derivados de benzimidazoles e imidazopiridinas, un procedimiento para su preparacion, composiciones farmaceuticas, un procedimiento para su preparacion, y un medicamento utiles como inhibidores de la replicacion del virus sincitial respiratorio
JP2010521483A5 (cg-RX-API-DMAC7.html)
AR057810A1 (es) Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo y composicion farmaceutica
AR082153A1 (es) N-sulfonilbenzamidas utiles como inhibidor del canal de sodio
AR063684A1 (es) Derivados de 4, 4´-bifenildiilbis(1h-imidazol-5, 2-diil) como inhibidores del virus de la hepatitis c, composicion que los comprende y su uso para tratar una infeccion con vhc.
AR050970A1 (es) Pirimidinas 5-sustituidas con carbociclos o heterociclos inhibidoras del vih; composiciones farmaceuticas que las contienen y uso de las mismas como medicamentos.
RU2008112290A (ru) Производные пиридазинона, используемые для лечения боли
RU2487124C2 (ru) Новое амидное производное и его использование в качестве лекарственного средства
AR067542A1 (es) Compuestos macrociclicos de indol utiles para el tratamiento de hepatitis c
AR073586A1 (es) Compuestos heterociclicos utiles para el tratamiento de vhc
AR081495A1 (es) Compuestos para el tratamiento de la hepatitis c
AR057872A1 (es) Inhibidores de la proteina activadora de 5-lipoxigenasa (flap)
AR065276A1 (es) Herbicidas de n-oxidos de piridina sustituidos
AR083070A1 (es) Analogos de nucleotidos sustituidos con heterociclos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos para tratar enfermedades virales, en particular infecciones por vhc
AR035716A1 (es) Compuestos agonistas del receptor beta3-adrenergico, uso de los mismos en la fabricacion de medicamentos y composiciones farmaceuticas conteniendo los mismos
IS8503A (is) Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
NO20091707L (no) Inhibitorer av hepatitt C virus
AR040475A1 (es) Espiropiperidinas o espiropirrolidinas triciclicas
AR044016A1 (es) Compuestos de 4-fenil piperidina y sus usos como moduladores de receptores opioides
AR071617A1 (es) Bencenosulfonamidas de oxazol y tiazol, composiciones farmaceuticas que las contienen, proceso de preparacion y uso de las mismas como agentes anticancerigenos.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal